Dr. Reddy’s Laboratories Ltd ADR 

€70.5
125
-€1-1.4% 오늘

통계

낮 최고
70.5
낮음
70.5
52W 높음
-
52W 낮음
-
거래량
0
평균 거래량
-
시가 총액
12.12B
주가수익률
19.81
배당수익률
0.6%
배당금
0.42

예정

배당금

0.6%배당수익률
10년 성장률
5.03%
5년 성장률
11.03%
3년 성장률
12.27%
1년 성장률
-1.34%

수익

25Oct예상
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
다음
0
0.33
0.67
1
예상 EPS
0.991896238265
실제 EPS
해당 없음

다른 인물도 팔로우하고 있습니다

이 목록은 Stock Events에서 RDDA.F을(를) 팔로우하는 사람들의 워치리스트에 기반한 것입니다. 이는 투자 권유가 아닙니다.

경쟁자

이 목록은 최근 시장 이벤트에 기반한 분석입니다. 투자 권장사항이 아닙니다.

개요

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Show more...
CEO
Mr. Gunupati Venkateswara Prasad B.E.
직원
27048
국가
US
ISIN
US2561352038
WKN
000659157

목록